Genprex to Participate at BIO Europe Spring 2025

Core Viewpoint - Genprex, Inc. is actively participating in BIO Europe Spring 2025 to showcase its gene therapies for cancer and diabetes, highlighting its commitment to developing innovative treatments for patients with limited options [1][2][3] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing advanced technologies to deliver disease-fighting genes [4] - The company's lead product candidate, Reqorsa® Gene Therapy, is under evaluation in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [4] - Genprex's diabetes gene therapy, GPX-002, aims to transform pancreatic alpha cells into functional beta-like cells to produce insulin, addressing both Type 1 and Type 2 diabetes [4] Conference Participation - Key executives, including Ryan Confer and Thomas Gallagher, will be attending BIO Europe Spring 2025 in Milan, Italy, to engage with industry groups and provide insights into the company's gene therapies [2][3] - The conference is expected to attract over 3,700 executives from biotech, pharma, and finance sectors, facilitating more than 20,000 one-on-one meetings [3]